Drug Trial Radar · NCT04904549
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
23,670
Actual
Start
May 26, 2021
Primary completion
Aug 31, 2024
Study completion Aug 31, 2024
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a booster injection of a CoV2 preS dTM-AS03 vaccine, in adults 18 years of age and older. A total of approximately 21 046 participants are planned to be enrolled (5080 per study intervention group in Stage 1 and 5443 per study intervention group in Stage 2). Initial, double-blind, primary series study design is planned for 365 days post-last Initial injection (ie, approximately 386 days total) for each participant. Based on decisions of the Study Oversight Group, Stage 1 and Stage 2 participants will be invited to participate in an unblinded Crossover / Booster study design with duration as follows: * For participants who initially received vaccine: 12 months post-booster (ie, approximately 18 to 24 months) * For participants who initially received placebo: ≥ 4 months post-last dose of the primary series + 12 months post-booster (ie, approximately 28 to 34 months) * For participants who do not consent to continue in the unblinded Crossover / Booster part of the study, all study procedures will be stopped and participants will be discontinued from the study.
Conditions
- COVID-19
Interventions
SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)Biological
Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection
SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)Biological
Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
PlaceboBiological
Pharmaceutical form: liquid. Route of administration: intramuscular administration.
SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccinationBiological
Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccinationBiological
Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1 and Stage 2: Number of Participants With Onset of Symptomatic Coronavirus Disease 2019 (COVID-19) EpisodeTime frame: From Day 36 up to Day 387
- Stage 1 and Stage 2: Number of Participants With Solicited Injection Site and Systemic ReactionsTime frame: Up to 7 days after each vaccination (post-dose on Days 1 and 22)
- Stage 1 and Stage 2: Number of Participants With Unsolicited Non-Serious Adverse Events (AEs)Time frame: Up to 21 days after each vaccination (post-dose on Days 1 and 22)
- Stage 1 and Stage 2: Number of Participants With Immediate Adverse EventsTime frame: Up to 30 minutes after each vaccination (post-dose on Days 1 and 22)
- Stage 1 and Stage 2: Number of Participants With Medically Attended Adverse Events (MAAE), Serious Adverse Events (SAE), and Adverse Events of Special Interest (AESI)Time frame: From first dose of study vaccine administration (Day 1) up to 387 days
- Stage 1 and Stage 2: Percentage of Participants With Virologically-Confirmed SARS-CoV-2 Infection and/or Symptomatic COVID-19Time frame: From first dose of study vaccine administration (Day 1) up to 387 days
Locations
86 sites in 11 countries. Site status is shown where the registry gives one.
AES - DRS - Simon Williamson Clinic, PC - Birmingham- Site Number : 8400004
Birmingham, Alabama
Optimal Research Alabama- Site Number : 8400019
Huntsville, Alabama
Peninsula Research Associates, Inc.- Site Number : 8400021
Rolling Hills Estates, California
Synexus Clinical Research US, Inc. Site Number : 8400013
Centennial, Colorado
Optimal Research, LLC-Melbourne- Site Number : 8400002
Melbourne, Florida
Synexus Clinical Research US, Inc. - Orlando- Site Number : 8400020
Orlando, Florida
AES St. Petersburg- Site Number : 8400017
Pinellas Park, Florida
Synexus Clinical Research US, Inc. - Atlanta- Site Number : 8400005
Atlanta, Georgia
Synexus Clinical Research Chicago- Site Number : 8400012
Chicago, Illinois
Synexus Clinical Research Evansville- Site Number : 8400008
Evansville, Indiana
Synexus St. Louis- Site Number : 8400006
St Louis, Missouri
Synexus Clinical Research US, Inc. - Henderson- Site Number : 8400018
Henderson, Nevada
Rochester Clinical Research, Inc.- Site Number : 8400023
Rochester, New York
Synexus Akron- Site Number : 8400009
Akron, Ohio
Synexus Clinical Research US, Inc. - Cincinnati- Site Number : 8400010
Cincinnati, Ohio
Synexus US Columbus- Site Number : 8400011
Columbus, Ohio
Synexus Clinical Research Anderson- Site Number : 8400007
Anderson, South Carolina
Coastal Carolina Research Center - N Charleston- Site Number : 8400022
North Charleston, South Carolina
American Indian Clinical Trials Research Network Site Number : 8400025
Rapid City, South Dakota
AES Austin- Site Number : 8400003
Austin, Texas
Synexus Dallas- Site Number : 8400014
Dallas, Texas
Synexus Clinical Research US, Inc. - San Antonio- Site Number : 8400015
San Antonio, Texas
AES Salt Lake City- Site Number : 8400016
Murray, Utah
Investigational Site Number : 1700010
Aguazul, Colombia
Investigational Site Number : 1700002
Barranquilla, Colombia
Investigational Site Number : 1700008
Barranquilla, Colombia
Investigational Site Number : 1700001
Bogotá, Colombia
Investigational Site Number : 1700005
Cali, Colombia
Investigational Site Number : 1700006
Chía, Colombia
Investigational Site Number : 1700004
Floridablanca, Colombia
Investigational Site Number : 1700007
Girardot, Colombia
Investigational Site Number : 1700009
Meta, Colombia
Investigational Site Number : 1700015
Quindío, Colombia
Investigational Site Number : 1700003
Soledad, Colombia
Investigational Site Number : 2880002
Kintampo, Ghana
Investigational Site Number : 2880003
Kumasi, Ghana
Investigational Site Number : 2880001
Navrongo, Ghana
Investigational Site Number : 3400001
Municipio Del Distrito Central, Honduras
Investigational Site Number : 3400002
San Pedro Sula, Honduras
Investigational Site Number : 3560010
Ajmer, India
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.